FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

nses)													
s of Reporting Person		2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD]				5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
· · · · · · · · · · · · · · · · · · ·		3. Date of Earliest Transaction (Month/Day/Year) 12/20/2018					X Officer (give title below) Other (specify below) Chief Medical Officer						
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person						
7 10016									_ Form filed by I	viore than One	Reporting Person		
(State)	(Zip)			Tabl	e I -	Non-Deriva	tive Securities	s Acquire	ed, Disposed	of, or Bene	eficially Own	ed	
	2. Transaction Date (Month/Day/Year)	Execution	on I	Date, if Co (In	ode istr.	(A) (In	or Disposed of str. 3, 4 and 5) (A) or	of (D) Ov Tr	wned Follow ansaction(s)		d 1	Ownership of Form: Direct (D) or Indirect (I)	eneficial wnership
3. Transaction				ılls, warra	nts,	form dis form dis prired, Dispos options, con	ed in this for plays a curr ed of, or Bene vertible secur	m are no ently val eficially C ities)	ot required lid OMB co Owned	to respon ntrol num	d unless the	e	74 (9-02)
ise (Month/Day/Year)	any	Code	de Securities (Month/Day/Year) Securit		Securitie	rities Secu		Securities I Beneficially I Owned S Following I Reported	Security: Direct (D) or Indirect	Beneficia			
		Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(Instr. 4)	(Instr. 4)		
	(First) THERAPEUTICS, E, 9TH FLOOR (Street) Y 10016 (State) a separate line for each or each	(First) (Middle) THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) Y 10016 (State) (Zip) 2. Transaction Date (Month/Day/Year) Table II - (Month/Day/Year) ye 3. Transaction Date Execution Date, if any (Month/Day/Year) (Month/Day/Year)	RELMA (First) (Middle) 3. Date of 12/20/2 E, 9TH FLOOR (Street) 4. If Amma 4. If Amma 5. If Amma 6. If Amma	RELMADA (First) (Middle) THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) 2. Transaction Date (Month/Day/Year) n a separate line for each class of securities beneficially Table II - Derivative S (e.g., puts, ca lion Date (Month/Day/Year) 3. Transaction Date Execution I any (Month/Day Table II - Derivative S (e.g., puts, ca lion Date (Month/Day/Year) (Instr. 8)	RELMADA THERA (First) (Middle) THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) 4. If Amendment, Date 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securities Acquired or Disposof (D) (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warra (Month/Day/Year) 3. Deemed Execution Date, if Code (Instr. 8) Execution Date, if Code (Instr. 8) Acquired or Disposof (D) (Instr. 3, 4)	RELMADA THERAPE (First) (Middle) THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) 4. If Amendment, Date Orig Y 10016 2. Transaction Date (Month/Day/Year) Cod Table II - Derivative Securities Acquee.g., puts, calls, warrants, and put of the put of th	RELMADA THERAPEUTICS, INC., The control of the cont	RELMADA THERAPEUTICS, INC. [RLMD] (First) (Middle) (THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (State) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	RELMADA THERAPEUTICS, INC. [RLMD] THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) A. Deemed Execution Date, if of care in a separate line for each class of securities beneficially owned directly or indirectly. Table II - Derivative Securities Acquired, Disposed of, or Beneficially of Code (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Code (A) or Disposed of (D) (Instr. 3, 4 and 5) Table II - Derivative Securities Acquired, Disposed of, or Beneficially or Disposed of (D) (Instr. 8) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) A. Securities Acquired, Disposed of, or Beneficially or Disposed of (D) (Instr. 8) Code (Month/Day/Year) Date Execution Date, if Transaction Date (Month/Day/Year) A. Deemed Execution Date, if On Date (Month/Day/Year) A. Deemed Execution Date, if On Date (Month/Day/Year) Date Execution Date (Month/Day/Year) Date Execution Date (Month/Day/Year) Date Expiration Title Title	RELMADA THERAPEUTICS, INC. [RLMD] Director	RELMADA THERAPEUTICS, INC. [RLMD] (First) (Fi	RELMADA THERAPEUTICS, INC. [RLMD] (First) (Middle) (First) (Middle) (THERAPEUTICS, INC., 750 RELMADA THERAPEUTICS, INC. [RLMD] (First) (Middle) (State) (Street) (State) (State) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3 and 4) (A) or Code (A) or Beneficially Owned (Instr. 3 and 4) (Instr. 3 and 4) (Check all applicable (Che	RELMADA THERAPEUTICS, ÎNC. [RLMD] (First) (Middle) THERAPEUTICS, INC., 750 E, 9TH FLOOR (Street) Y 10016 (State) (State) (State) (State) (State) (State) (State) (State) (State) (Zap) Table 1 - Non-Derivative Securities Acquired, Date (Month/Day/Year) (Month/Day/Year)

Donation Common Name / Addison	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Vitolo Ottavio V. C/O RELMADA THERAPEUTICS, INC. 750 THIRD AVENUE, 9TH FLOOR NEW YORK, NY 10016			Chief Medical Officer				

Signatures

/s/ Ottavio V. Vitolo	12/20/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.